RxDoctor Payments Data

David Wanner, DPM

Podiatrist · Ottumwa, IANPI 1558566208

Payments from drug & device makers

What this record shows

This record is dominated by other: $4,000 of the $5,787 with a category attached, or 69.1%. Acera Surgical, Inc. accounts for 69.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $4,181 and has fallen 99.2% since, to $35 in 2025.

$5,787in general payments, 2019–2025

Across 51 payments — averaging $113.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acera Surgical, Inc.$4K
  • Kerecis Limited$516
  • Reprise Biomedical, Inc.$369
  • Organogenesis Inc.$211
  • Osiris Therapeutics Inc.$151
  • Smith+Nephew$112
  • plus $428 from 10 others

What the payments were for

  • Food & beverage$1,78731%
  • Other$4,00069%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,787 in reported general payments places this provider in the 75th percentile of 94 podiatrist providers in Iowa.

See all podiatrist providers in Iowa

Medicare billing

Part B allowed, 2024
$1,517,081
Medicare patients
279
Services billed
2,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin80$1,225
Pregabalin23$431
Celecoxib24$405
Meloxicam121$355
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$295
Ciclopirox11$256
Methylprednisolone31$230
Nabumetone11$120
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$105
Allopurinol30$70
Tramadol Hcl11$15

Paid to pharmacies, not to this prescriber.

Other podiatrist in Ottumwa

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →